Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy

• Published in: Current cardiology reports 2021-03, Vol.23 (3), p.16, Article 16
• Main Authors: Chen, Daniel H., Tyebally, Sara, Malloupas, Michael, Roylance, Rebecca, Spurrell, Emma, Raja, Fharat, Ghosh, Arjun K.
• Format: Article
• Language: English
• Subjects: Anthracyclines; Antineoplastic Agents - adverse effects; Breast Neoplasms - drug therapy; Breast Neoplasms - radiotherapy; Cardio-Oncology (TG Neilan; Cardiology; Cardiotoxicity - drug therapy; Cardiotoxicity - etiology; Cardiovascular Diseases - chemically induced; Female; Humans; Medicine; Medicine & Public Health; Neoplasm Recurrence, Local; Section Editor; Topical Collection on Cardio-Oncology; Trastuzumab - adverse effects
• ISSN: 1523-3782; 1534-3170
• DOI: 10.1007/s11886-021-01446-x

Purpose of Review Cardiotoxicity can occur acutely during breast cancer treatment and impact the potential for the intended cancer treatment regime to be completed, or as a late effect affecting cancer survivorship. Indeed, the most common cause of mortality in females with early breast cancer is cardiovascular disease, especially in those over the age of 65. Optimal cancer care therefore needs to be delivered without jeopardising cardiovascular health. Understanding the different cardiotoxicities associated with breast cancer treatment is vital to this approach, and therefore, this article seeks to provide an overview of this. Recent Findings Tyrosine kinase inhibitors targeting human epidermal growth factor receptor (HER)-2, immune checkpoint inhibitors (ICI), and cyclin-dependent kinase (CDK) inhibitors are new targeted breast cancer treatments. In particular, ICI are associated with myocarditis that carries a significant mortality, whilst the CDK inhibitor ribociclib causes QT prolongation that requires cardiac surveillance and appropriate dose adjustment to prevent ventricular arrhythmias. The need has always been for strategies to mitigate the risks of cardiovascular toxicities, and new data is promising for the use of dexrazoxane in anthracyclines, and the role of beta blockers and angiotensin converting enzymes inhibitors in anthracyclines and HER-2 monoclonal antibodies such as trastuzumab. Summary Significant headways in breast cancer treatment have resulted in reductions in disease recurrence and mortality, but cardiovascular complications continue to impact the ability to deliver some of these cancer treatments, and the period of cancer survivorship.